Global contract research organization (CRO), Fortrea today announced an industry partnership with founding members cloud solutions company Veeva Systems Inc., and provider of clinical research technology, Advarra.
A not-for-profit organization, Medicines Development for Global Health (MDGH), that develops medicines for neglected diseases in low- and middle-income countries, will benefit from support from contract research organization (CRO), Phastar.
A transaction between Citius Pharmaceuticals and TenX Keane which will result in the formation of Citius Oncology, Inc. is due to close in the first half of next year (2024).
Integrated drug discovery contract research organization (CRO) Sygnature Discovery has invested £3.75 million in an Azenta compound management storage system that can also provide customer libraries.
Contract research organization (CRO), Phastar, has had its net-zero target approved by SBTi which it hopes to achieve by adopting stringent sustainability standards.
OSP spoke to Vesta Marciulioniene, director global regulatory clinical services at ICON Biotech, a contract research organisation who shares insights on the new EMA guideline for computerised systems and electronic data in clinical trials and what new...
Phastar, a biometrics contract research organization (CRO) can now officially call its business ‘a force for good’ after it received B Corp certification.
Two contract research organizations working in the clinical trial and research fields have benefited from investment from Iberian private equity firm, Henko Partners.
The German and Spanish companies use their relevant expertise in conjunction to provide clients with services spanning from hit generation to pre-clinical development.
The two French-based companies announced a strategic collaboration at the end of last month (March 2023) that saw Galapagos’ employees working in the research and discovery departments and transferred across to the contract research organization (CRO)....
Canadian CRO Nutrasource Pharmaceutical and Nutraceutical Services Inc has rebranded its clinical trial site as Apex Trials to expand its focus beyond food & natural health product trials.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
The CRO focuses its services towards biotechs by stating that they are cheaper and more efficient compared to rivals, and it was this principle that drew in General Catalyst to provide investment.
Australian CRO Avance Clinical has expanded in North America by acquiring C3 Research Associates, positioning it to continue supporting sponsors as they move into later-phase studies that need US sites.
The virtual contract research organization (VCRO) Curavit Clinical Research has entered a long-term partnership with ixlayer. The partnership ushers in convenience for patients in Curavit’s trials.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
A leader from the CRO discusses how capturing the perspective of trial participants can help ensure development of treatments that meet the patients’ needs.
A leader from the site management organization, which already has expanded since opening in 2019, is planning on adding sites and talent to its roster.
Michelle Keefe, formerly the president of medical affairs and commercial solutions, joined the company in 2017; she also had spent 20 years working for Pfizer
A leader from the VCRO shares how far the industry has come with decentralized adoption, where opportunities for improvement exist, and what lies ahead.
With a specific focus on clinical trials involving treatments for rare diseases, Orphan Reach seeks to build upon the services that conventional CROs offer.
The two companies, which have been collaborating for 15 years, reportedly will focus on elevating decentralized trial solutions to develop new therapies.
The CRO is helping out on a project exploring the effects of the virus in children; other members of the research team include experts from Duke University.
In this second of a two-part series, experts from the clinical research organization share thoughts on how data management technology, personnel, and partnerships have evolved.
In the first of a two-part series, leaders from the CRO discuss how study data has progressed in recent years and how trial teams can keep up effectively.
This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
According to data released by the company, the majority of study professionals plan to run agile or hybrid trials over the course of the next 12 months.
A study by Charles River finds patients believe the overall quality of healthcare would increase if stakeholders across the life sciences collaborated more.
Conducted by patient services specialist Greenphire, the survey checks in with contract research organizations and shows how they are approaching obstacles.
A logistics leader from the CRO offers advice on navigating borders, cultures, regulatory issues and other important considerations on worldwide studies.
Two experts from the contract research organization offer advice on planning and executing clinical studies with the unique needs of such patients in mind.
This month’s news on hires, promotions, acquisitions, expansions, and funding includes items about Syneos Health, ProSciento, Phastar, CPhI, Immunai, and other key industry players.
A recent check-in with several biopharma and CRO companies, conducted by Life Science Strategy Group, indicates adjustment to pandemic-related challenges.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
Aiming to support drug developers in issues related to market insights, engagement, and access, Synaptiq enters the market backed by three consultancy agencies.
dMed Biopharmaceutical recently raised approximately $50m in a Series B financing to further expand the CRO’s operations after launching three years ago.
phaseUP is a new life sciences leadership firm that is looking to help pharma, biotech, and CROs build cohesive and collaborative teams – as the success or failure of a clinical development program depends on the people, says company founder.
With global health care ‘at a tipping point,’ NSF International expands its services across the product lifecycle with the acquisition of a US-headquartered CRO, says VP.
The CRO has opened a new clinic in response to demand for early-stage research, specifically for Alzheimer’s Disease, and expanded its footprint in India to conduct studies ‘at favorable pricing with faster timelines,’ say company executives.
In response to demand for flexibility, Cromsource has consolidated its hybrid services model to provide customers with an alternative to fully outsourced or functional service provider (FSP) models.
The digital health company AMRA has entered into an exclusive agreement with the largest imaging CRO in Japan as part of its work to provide ‘critical informatics’ to the drug development industry.
Harbour BioMed has selected PPD as its preferred CRO partner as part of a strategic collaboration to develop novel oncology and immunology therapeutics.
Frontage Clinical Services has expanded its site in New Jersey to accommodate nicotine-related studies and is developing a portfolio of assays to evaluate tobacco-specific biomarkers.